BRIEF-Agios Provides Update On Phase 2 Trial Of Tebapivat In Sickle Cell Disease

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO

0.00

July 21 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:

  • AGIOS PROVIDES UPDATE ON PHASE 2 TRIAL OF TEBAPIVAT IN SICKLE CELL DISEASE

  • AGIOS PHARMACEUTICALS - WILL NOT ADVANCE TEBAPIVAT IN SICKLE CELL DISEASE

  • AGIOS PHARMACEUTICALS - PRIMARY ENDPOINT ACHIEVED BY UP TO 47.1% IN TEBAPIVAT ARMS; 33.3% IN PLACEBO ARM

  • AGIOS PHARMACEUTICALS - TEBAPIVAT SAFETY CONSISTENT WITH PRIOR SICKLE CELL DISEASE TRIALS

  • AGIOS PHARMACEUTICALS - FDA PRIORITY REVIEW FOR MITAPIVAT IN SICKLE CELL DISEASE; PDUFA DATE NOVEMBER 1, 2026

Source text: ID:nGNXbgGfWJ

Further company coverage: AGIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.